| First Author | Poelzl A | Year | 2021 |
| Journal | Cell Death Differ | Volume | 28 |
| Issue | 2 | Pages | 748-763 |
| PubMed ID | 32929218 | Mgi Jnum | J:302820 |
| Mgi Id | MGI:6510111 | Doi | 10.1038/s41418-020-00621-x |
| Citation | Poelzl A, et al. (2021) TYK2 licenses non-canonical inflammasome activation during endotoxemia. Cell Death Differ 28(2):748-763 |
| abstractText | The non-canonical inflammasome is an emerging crucial player in the development of inflammatory and neurodegenerative diseases. It is activated by direct sensing of cytosolic lipopolysaccharide (LPS) by caspase-11 (CASP11), which then induces pyroptosis, an inflammatory form of regulated cell death. Here, we report that tyrosine kinase 2 (TYK2), a cytokine receptor-associated kinase, is a critical upstream regulator of CASP11. Absence of TYK2 or its kinase activity impairs the transcriptional induction of CASP11 in vitro and in vivo and protects mice from LPS-induced lethality. Lack of TYK2 or its enzymatic activity inhibits macrophage pyroptosis and impairs release of mature IL-1beta and IL-18 specifically in response to intracellular LPS. Deletion of TYK2 in myeloid cells reduces LPS-induced IL-1beta and IL-18 production in vivo, highlighting the importance of these cells in the inflammatory response to LPS. In support of our data generated with genetically engineered mice, pharmacological inhibition of TYK2 reduced LPS-induced upregulation of CASP11 in bone marrow-derived macrophages (BMDMs) and of its homolog CASP5 in human macrophages. Our study provides insights into the regulation of CASP11 in vivo and uncovered a novel link between TYK2 activity and CASP11-dependent inflammation. |
